Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-5257Fax+1 617-726-4899
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997- Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1994
Duke University School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1994 - 2025
NH State Medical License 2024 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2003 Sep 01
- Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy Start of enrollment: 2006 Mar 01
- Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2002 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 80 citationsNiraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.Kim N Chi, Dana Rathkopf, Matthew R Smith, Eleni Efstathiou, Gerhardt Attard
Journal of Clinical Oncology. 2023-06-20 - 54 citationsDarolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARAS...Maha Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N Sternberg
Journal of Clinical Oncology. 2023-07-10 - 1067 citationsDiabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerNancy L. Keating, A. James O'Malley, Matthew R. Smith
Journal of Clinical Oncology. 2006-09-20
Other
- Initial hormone therapy for metastatic prostate cancerSmith MR, Lee RJ
http://www.uptodate.com/contents/initial-hormone-therapy-for-metastatic-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09 - Side effects of androgen deprivation therapySmith MR, Crawford ED
http://www.uptodate.com/contents/side-effects-of-androgen-deprivation-therapy
UpToDate, Wolters Kluwer Health - 2013-03-27
Press Mentions
Darolutamide Ups Survival in Metastatic Hormone-Sensitive Prostate CancerFebruary 17th, 2022- Another PARP Inhibitor Active in BRCA-Mutant Prostate CancerFebruary 8th, 2022
- Accelerating Precision Medicine in Metastatic Prostate CancerNovember 17th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
